These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 14572601)

  • 21. Diffuse cutaneous eruption due to interferon alfa and ribavirin treatment of chronic hepatitis C.
    Savk E; Uslu G; Karaoğlu AO; Sendur N; Karaman G
    J Eur Acad Dermatol Venereol; 2005 May; 19(3):396-8. PubMed ID: 15857485
    [No Abstract]   [Full Text] [Related]  

  • 22. Treatment of hepatitis C virus: the first decade.
    Poynard T
    Semin Liver Dis; 2004; 24 Suppl 2():19-24. PubMed ID: 15346242
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Concurrent antiphospholipid syndrome and cutaneous [corrected] sarcoidosis due to interferon alfa and ribavirin treatment for hepatitis C.
    Shinohara MM; Davis C; Olerud J
    J Drugs Dermatol; 2009 Sep; 8(9):870-2. PubMed ID: 19746680
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Development of Myasthenia gravis due to treatment of chronic hepatitis C with a combination of interferon-alpha and ribavirin.
    Bektas M; Bektas H; Gören D; Altan M; Cetinkaya H
    Digestion; 2007; 75(4):208-9. PubMed ID: 17934275
    [No Abstract]   [Full Text] [Related]  

  • 25. Lichen aureus induced by interferon-alpha plus ribavirin.
    González-Sixto B; García-Doval I; Conde A; Mayo E; Pardavila R; De La Torre C; Cruces M
    Acta Derm Venereol; 2007; 87(1):87-8. PubMed ID: 17225027
    [No Abstract]   [Full Text] [Related]  

  • 26. Chronic viral hepatitis.
    Dakhil N; Junaidi O; Befeler AS
    Mo Med; 2009; 106(5):361-5. PubMed ID: 19902718
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The role of thyroid autoantibodies in the development of thyroid dysfunction in Taiwanese chronic hepatitis C patients with interferon-alpha and ribavirin combination therapy.
    Huang JF; Chuang WL; Dai CY; Chen SC; Lin ZY; Lee LP; Lee PL; Wang LY; Hsieh MY; Chang WY; Yu ML
    J Viral Hepat; 2006 Jun; 13(6):396-401. PubMed ID: 16842442
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [The influence of HCV infection and immunomodulating therapy (interferon-alpha and ribavirin) on the condition of minor salivary glands and oral mucosa].
    Sulka A; Simon K; Jeleń M; Piszko P
    Przegl Epidemiol; 2005; 59(2):455-66. PubMed ID: 16190554
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Consensus interferon and ribavirin for patients with chronic hepatitis C and failure of previous interferon-alpha therapy.
    Böcher WO; Schuchmann M; Link R; Hillenbrand H; Rahman F; Sprinzl M; Mudter J; Löhr HF; Galle PR
    Liver Int; 2006 Apr; 26(3):319-25. PubMed ID: 16584394
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Chronic hepatitis C and B. What can be accomplished with antiviral therapy].
    MMW Fortschr Med; 2007 Feb; 149(7):14. PubMed ID: 17615650
    [No Abstract]   [Full Text] [Related]  

  • 31. The effect of interferon alpha plus ribavirin on health-related quality of life in chronic C hepatitis. The Romanian experience.
    Pojoga C; Dumitraşcu DL; Pascu O; Grigorescu M
    J Gastrointestin Liver Dis; 2006 Mar; 15(1):31-5. PubMed ID: 16680230
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Vitamins B depletion, lower iron status and decreased antioxidative defense in patients with chronic hepatitis C treated by pegylated interferon alfa and ribavirin.
    Lin CC; Yin MC
    Clin Nutr; 2009 Feb; 28(1):34-8. PubMed ID: 19042060
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Treatment with natural interferon (alfaferone) in clinical practice--our experience].
    Dybowska D; Halota W
    Przegl Epidemiol; 2007; 61(1):17-22. PubMed ID: 17702434
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Interferon alpha. Effect, indications, therapy monitoring and side-effects].
    Kraus MR; Wilms K
    Internist (Berl); 2000 Dec; 41(12):1399-404. PubMed ID: 11189075
    [No Abstract]   [Full Text] [Related]  

  • 35. [Antiviral therapy of chronic viral hepatitis].
    Trautwein C; Manns MP
    Internist (Berl); 2001 Jun; 42(6):913-23. PubMed ID: 11449639
    [No Abstract]   [Full Text] [Related]  

  • 36. [Experience in heptral treatment of diffuse liver diseases].
    Gorbakov VV; Galik VP; Kirillov SM
    Ter Arkh; 1998; 70(10):82-6. PubMed ID: 9864813
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Onset of coeliac disease and interferon treatment.
    Bourlière M; Oulés V; Perrier H; Mengotti C
    Lancet; 2001 Mar; 357(9258):803-4. PubMed ID: 11253998
    [No Abstract]   [Full Text] [Related]  

  • 38. Treating chronic Hepatitis C patients with psychiatric disorders: an uphill battle.
    Cheung R; Ahmed A
    Am J Gastroenterol; 2001 Jan; 96(1):3-4. PubMed ID: 11197283
    [No Abstract]   [Full Text] [Related]  

  • 39. [Chronic hepatitis. 5: Therapy of chronic viral hepatitis, especially hepatitis C].
    Schlaak JF; Gerken G
    Fortschr Med; 1997 Sep; 115(25):48-50. PubMed ID: 9378444
    [No Abstract]   [Full Text] [Related]  

  • 40. ABC of diseases of liver, pancreas, and biliary system: Chronic viral hepatitis.
    Ryder SD; Beckingham IJ
    BMJ; 2001 Jan; 322(7280):219-21. PubMed ID: 11159624
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.